RxDoctor Payments Data

Valentine Anyiam, MD

Psychiatry · The Villages, FLNPI 1730683194

Payments from drug & device makers

$4,230in general payments, 2019–2025

Across 109 payments — averaging $38.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$960
  • Axsome Therapeutics, Inc.$561
  • Otsuka America Pharmaceutical, Inc.$535
  • AbbVie$502
  • Neuronetics, Inc.$484
  • Neurocrine Biosciences, Inc.$357
  • plus $830 from 10 others

What the payments were for

  • Food & beverage$4,230100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,230 in reported general payments places this provider in the 75th percentile of 2,059 psychiatry providers in Florida.

See all psychiatry providers in Florida

Medicare billing

Part B allowed, 2024
$109,960
Medicare patients
65
Services billed
855

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole28$44,799
CaplytaLumateperone Tosylate21$38,250
VraylarCariprazine Hcl18$28,880
TrintellixVortioxetine Hydrobromide16$12,071
NuedextaDextromethorphan Hbr/Quinidine12$9,107
Aripiprazole65$8,231
Desvenlafaxine Succinate ErDesvenlafaxine Succinate45$3,756
Atomoxetine Hcl11$3,738
Ramelteon17$3,170
Vilazodone Hcl12$2,553
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine61$2,343
Venlafaxine Hcl ErVenlafaxine Hcl119$2,057
Duloxetine Hcl109$1,724
Trazodone Hcl135$1,576
Quetiapine Fumarate68$1,346

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$535$44,79928 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$960$38,25021 claims
AbbVieVraylar$502$28,88018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,059 psychiatry providers in Florida.

Other psychiatry in The Villages

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →